Selective Inhibition of the Interaction between SARS-CoV-2 Spike S1 and ACE2 by SPIDAR Peptide Induces Anti-Inflammatory Therapeutic Responses.
Selective Inhibition of the Interaction between SARS-CoV-2 Spike S1 and ACE2 by SPIDAR Peptide Induces Anti-Inflammatory Therapeutic Responses.
复制标题
DOI:
10.4049/jimmunol.2100144
复制
发表时间:
2021-11-15
期刊:
影响因子:
--
通讯作者:
Pahan K
中科院分区:
文献类型:
--
作者:
Paidi RK;Jana M;Mishra RK;Dutta D;Pahan K
Many COVID-19 patients in intensive care units suffer from cytokine storm. Although anti-inflammatory therapies are available to treat the problem, very often these treatments cause immunosuppression. Since angiotensin-converting enzyme 2 (ACE2) on host cells serves as the receptor for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in order to delineate SARS-CoV-2-specific anti-inflammatory molecule, we designed a hexapeptide corresponding to the Spike S1-Interacting Domain of ACE2 Receptor (SPIDAR) that inhibited the expression of proinflammatory molecules in human A549 lung cells induced by pseudotyped SARS-CoV-2, but not vesicular stomatitis virus (VSV). Accordingly, wild type (wt), but not mutated (m), SPIDAR inhibited SARS-CoV-2 spike S1-induced activation of NF-κB and expression of IL-6 and IL-1β in human lungs cells. However, wtSPIDAR remained unable to reduce activation of NF-κB and expression of proinflammatory molecules in lungs cells induced by TNFα, HIV-1 Tat, and viral double-stranded RNA mimic poly IC, indicating the specificity of the effect. The wtSPIDAR, but not mSPIDAR, also hindered the association between ACE2 and spike S1 of SARS-CoV-2 and inhibited the entry of pseudotyped SARS-CoV-2, but not VSV, into human ACE2-expressing HEK293 cells. Moreover, intranasal treatment with wtSPIDAR, but not mSPIDAR, inhibited lung activation of NF-κB, protected lungs, reduced fever, improved heart function, and enhanced locomotor activities in SARS-CoV-2 spike S1-intoxicated mice. Therefore, selective targeting of SARS-CoV-2 spike S1-to-ACE2 interaction by wtSPIDAR may be beneficial for COVID-19.
登录
查看更多内容
影响因子:
20.1
作者:
Patel VB;Zhong JC;Grant MB;Oudit GY
通讯作者:
Oudit GY
影响因子:
4.4
作者:
Jana, Malabendu;Jana, Arundhati;Pahan, Kalipada
通讯作者:
Pahan, Kalipada
影响因子:
6.2
作者:
Jana, Arundhati;Modi, Khushbu K.;Roy, Avik;Anderson, John A.;van Breemen, Richard B.;Pahan, Kalipada
通讯作者:
Pahan, Kalipada
DOI:
10.1007/s11481-020-09979-8
发表时间:
2021-03
期刊:
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
影响因子:
--
作者:
Paidi RK;Jana M;Mishra RK;Dutta D;Raha S;Pahan K
通讯作者:
Pahan K
DOI:
10.1038/nrmicro2090
发表时间:
2009-03
期刊:
Nature reviews. Microbiology
影响因子:
--
作者:
通讯作者:
--